Patent holdings for IPC class A61K 31/137

Total number of patents in this class: 4752

10-year publication summary

376
371
401
405
429
412
373
350
293
46
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026

Principal owners for this class

Owner
All patents
This class
Antecip Bioventures II LLC
349
199
Novartis AG
10481
54
The Regents of the University of California
20366
51
Grünenthal GmbH
544
42
Zogenix International Limited
76
42
Axsome Therapeutics, Inc.
310
39
Nalpropion Pharmaceuticals LLC
69
39
The Procter & Gamble Company
21977
38
Nevakar Injectables Inc.
45
31
Aquestive Therapeutics, Inc.
185
28
Noven Pharmaceuticals, Inc.
89
27
Radius Pharmaceuticals, Inc.
56
26
The Trustees of Columbia University in the City of New York
3614
23
Gruenenthal GmbH
100
23
Pharnext
85
22
Duke University
3157
21
Institut National de La Sante et de La Recherche Medicale (inserm)
3084
21
Ironshore Pharmaceuticals & Development, Inc.
37
20
The United States of America, as represented by the Secretary, Department of Health and Human Services
2943
20
Clexio Biosciences Ltd.
101
19
Other owners 3967